Context Capital Management’s Clarus Therapeutics Holdings, Inc. Warrants CRXTW Stock Holding History

Context Capital Management’s Portfolio CRXTW Stock Details CRXTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-62,175	Closed	–	–	627
2022 Q3	$0	Hold	62,175	–	–	﹤0.01%	641
2022 Q2	$5K	Hold	62,175	–	–	﹤0.01%	569
2022 Q1	$9K	Sell	62,175 -25,000	-29%	-$4.54K	﹤0.01%	657
2021 Q4	$25K	Sell	87,175 -30,136	-26%	-$15.4K	﹤0.01%	516
2021 Q3	$88K	Buy	117,311 +5,965	+5%	+$4.5K	0.01%	381
2021 Q2	$84K	Sell	111,346 -5,400	-5%	-$3.39K	0.01%	439
2021 Q1	$64K	Buy	+116,746	New	+$93.4K	0.01%	415

Context Capital Management's CRXTW Position: Q4 2022 in Review

Context Capital Management sold out of Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) in Q4 2022, closing a stake of 62,175 shares.

Context Capital Management first reported a position in CRXTW in Q1 2021 and held it in 7 quarters. The position peaked at $88K in Q3 2021. 0 funds tracked by Wall St. Rank hold CRXTW as of Q4 2022.

Context Capital Management reported no remaining Clarus Therapeutics Holdings, Inc. Warrants position as of Q4 2022 after selling out during the quarter.
Context Capital Management sold 62,175 Clarus Therapeutics Holdings, Inc. Warrants shares in Q4 2022.
Context Capital Management first reported a position in Clarus Therapeutics Holdings, Inc. Warrants in Q1 2021 and held it in 7 quarters.
Context Capital Management's Clarus Therapeutics Holdings, Inc. Warrants position peaked at $88K in Q3 2021.
0 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Warrants as of Q4 2022.

Based on Context Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.